New hope drug tested for Tough-to-Treat prostate cancer
NCT ID NCT06104449
Summary
This is an early-stage study to check the safety and how the body processes a new drug called MK-5684 (opevesostat) in Japanese men with advanced prostate cancer. The cancer has spread and no longer responds to standard hormone therapy or chemotherapy. The main goal is to see what side effects occur and how the drug moves through the body in this small group of six participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital East ( Site 0001)
Kashiwa, Chiba, 277-8577, Japan
-
Toho University Sakura Medical Center ( Site 0003)
Sakura, Chiba, 285-8741, Japan
-
Yokohama City University Medical Center ( Site 0002)
Yokohama, Kanagawa, 232-0024, Japan
Conditions
Explore the condition pages connected to this study.